Affinage

PPP1R12A

Protein phosphatase 1 regulatory subunit 12A · UniProt O14974

Length
1030 aa
Mass
115.3 kDa
Annotated
2026-06-10
100 papers in source corpus 35 papers cited in narrative 34 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PPP1R12A (MYPT1) is the regulatory targeting subunit of myosin light chain phosphatase (MLCP), directing the PP1 catalytic subunit to dephosphorylate myosin regulatory light chain (MLC) and thereby controlling actomyosin contractility, cytoskeletal remodeling, and morphogenesis (PMID:24712327, PMID:20147380, PMID:24951589). Holoenzyme assembly is driven by an N-terminal region of MYPT1 in which a transient α-helix (residues ~1–40) becomes fully structured upon PP1 binding, adjacent to an ankyrin-repeat domain, and PP1 binding is required to redirect MYPT1 from the nucleus to the cytosol and myofilaments (PMID:21142030, PMID:16106448). MLCP activity is set by multisite, opposing phosphorylation: Rho-kinase phosphorylates inhibitory sites Thr-696 and Thr-853 (Thr-696 causing autoinhibitory substrate docking), through defined docking motifs near these sites, to inactivate the phosphatase (PMID:10579722, PMID:24712327, PMID:35204659), whereas PKG/PKA phosphorylation at Ser-668/Ser-695/Ser-667 activates MLCP and sterically blocks the inhibitory Thr-696 phosphorylation in a mutual-exclusion mechanism (PMID:15194681, PMID:25168281, PMID:21890627). MYPT1 abundance and activity are further tuned by SETD7/LSD1 methylation at Lys-442 governing proteasomal stability, SIAH2-mediated degradation, displacement from PP1cβ by the competing subunit TIMAP, and O-GlcNAcylation that antagonizes inhibitory phosphorylation to preserve phosphatase activity against procontractile lipid signaling (PMID:21115810, PMID:19744480, PMID:31315927, PMID:32929277, PMID:34019870). Beyond contractility, MYPT1/PP1β acts as a scaffold integrating cell-cycle and transcriptional control: LATS1, Chk1, and Chk2 phosphorylate MYPT1 (at Ser-445, Ser-20, and Ser-507) to license dephosphorylation and inactivation of PLK1, enforcing DNA-damage checkpoints and controlling centrosome maturation (PMID:22641346, PMID:29262732, PMID:31416392), while MYPT1/PP1β dephosphorylates EZH2-S21 to restrain EMT programs and promotes YAP/TAZ activation at recycling endosomes (PMID:35293697, PMID:36175407, PMID:37957190). MYPT1 is essential for early mouse embryogenesis and for vertebrate tissue morphogenesis, including coordinated mesoderm/endoderm movements and epithelial relaxation during brain ventricle expansion (PMID:16145842, PMID:18776143, PMID:20147380).

Mechanistic history

Synthesis pass · year-by-year structured walk · 33 steps
  1. 1999 High

    Established the central inhibitory input to MLCP by showing Rho-kinase directly phosphorylates MYPT1 to inactivate myosin phosphatase, linking Rho signaling to contractility and cytokinesis.

    Evidence Phospho-specific antibodies, dominant-negative Rho-kinase/C3 microinjection and immunofluorescence in MDCK and REF52 cells

    PMID:10579722

    Open questions at the time
    • Did not resolve the structural basis of inhibition
    • Relative contribution of Thr-696 vs Thr-853 not dissected
  2. 2000 Medium

    Identified PKC as a second kinase input acting near the PP1-binding motif, showing phosphorylation reduces both PP1c and substrate binding.

    Evidence In vitro phosphorylation, phosphatase activity and binding-competition assays with recombinant MYPT1(1-296)

    PMID:11068043

    Open questions at the time
    • Cellular relevance not tested
    • Second PKC site within ankyrin repeats not precisely mapped
  3. 2002 Medium

    Showed phospho-MYPT1 is highly resistant to dephosphorylation by major phosphatase classes, explaining persistence of the inhibited state.

    Evidence In vitro dephosphorylation assays with purified PP1/PP2A/PP2B/PP2C and smooth muscle fibers

    PMID:11943207

    Open questions at the time
    • The physiological phosphatase that reverses MYPT1 phosphorylation not identified
  4. 2004 High

    Defined the activating arm of MLCP regulation: PKG/PKA phosphorylation at Ser-695 sterically excludes inhibitory Thr-696 phosphorylation, providing a molecular basis for cGMP/cAMP Ca2+ desensitization.

    Evidence In vitro kinase assays and permeabilized ileum smooth muscle with constitutively active MYPT1K and 8-Br-cGMP

    PMID:15194681

    Open questions at the time
    • Did not establish in vivo requirement of this site for relaxation
    • Functional consequence of Ser-695 phosphorylation on activity not directly measured
  5. 2004 Medium

    Mapped the MYPT1 N-terminus (1–296) as the functional module sufficient to enhance MLC phosphorylation in intact tissue.

    Evidence TAT-mediated transduction of MYPT1 fragments into porcine coronary artery with force and MLC phosphorylation readouts

    PMID:14707041

    Open questions at the time
    • Did not separate PP1-binding from substrate-targeting contributions
  6. 2005 Medium

    Demonstrated that PP1 binding controls MYPT1 subcellular destination, redirecting it from nucleus to cytosol/myofilaments, and identified the C-terminus as autoinhibitory.

    Evidence Expression of tagged MYPT1/HA-PP1 and F38A mutant with immunofluorescence in REF52 fibroblasts

    PMID:16106448

    Open questions at the time
    • Nuclear function of free MYPT1 not characterized
    • Mechanism of C-terminal autoinhibition not defined
  7. 2005 High

    Established MYPT1 as essential for early mammalian development through constitutive knockout lethality.

    Evidence Mouse gene targeting with embryonic-lethality phenotyping before E7.5

    PMID:16145842

    Open questions at the time
    • Cell-type and pathway responsible for lethality not resolved
  8. 2006 Medium

    Localized the PKGIα-binding determinant to MYPT1 residues 888–928 via an RK motif, refining how the activating kinase is docked.

    Evidence Co-IP of MYPT1 deletion/point mutants with PKGIα in avian smooth muscle lysates

    PMID:16870832

    Open questions at the time
    • Single tissue system
    • Structural detail of the interaction absent
  9. 2008 High

    Defined an in vivo morphogenetic role: Mypt1 coordinates mesoderm/endoderm movements via actin organization, with loss causing liver agenesis.

    Evidence Zebrafish mutant analysis, 3D cell tracking, actin and Bmp2a staining, apoptosis assays

    PMID:18776143

    Open questions at the time
    • Direct phosphatase substrates driving the movement defect not identified
  10. 2008 Medium

    Connected MYPT1 regulation to a disease-relevant ligand, showing apolipoprotein(a) activates Rho/ROCK to phosphorylate MYPT1 and increase endothelial permeability.

    Evidence Recombinant apo(a) variants, Y27632/ε-aminocaproic acid rescue, permeability assays in HUVECs

    PMID:18776185

    Open questions at the time
    • Mechanism upstream of Rho activation by apo(a) not resolved
  11. 2009 Medium

    Identified SIAH2 as an E3 ligase that targets MYPT1 for proteasomal degradation, adding stability control to MLCP regulation.

    Evidence Co-IP, deletion-mapping of a degenerate Siah-binding motif, proteasome inhibitor experiments

    PMID:19744480

    Open questions at the time
    • Physiological trigger for SIAH2-mediated MYPT1 turnover not defined
  12. 2009 Medium

    Revealed a non-phosphatase function: MYPT1 is an FIH substrate whose ankyrin-domain hydroxylation competes with HIF-CAD to modulate HIF activity.

    Evidence FIH hydroxylation assays in cells and endogenous protein, FIH manipulation, HIF-CAD competition

    PMID:19245366

    Open questions at the time
    • Functional consequence of hydroxylation for MLCP activity unknown
  13. 2010 High

    Provided the structural mechanism of holoenzyme assembly: a transient N-terminal α-helix folds upon PP1 binding, driving MYPT1-PP1 complex formation.

    Evidence NMR spectroscopy and ensemble modeling of free vs PP1-bound MYPT1(1-98)

    PMID:21142030

    Open questions at the time
    • Did not include the full myosin-targeting C-terminus
  14. 2010 High

    Linked methylation to MYPT1 stability and cell-cycle control: SETD7 methylation at Lys-442 stabilizes MYPT1 while LSD1 demethylation destabilizes it, affecting RB1 dephosphorylation.

    Evidence In vitro methylation, SETD7/LSD1 manipulation, RB1 phosphorylation readouts, SETD7-deficient cells

    PMID:21115810

    Open questions at the time
    • Direct demonstration that MYPT1/PP1 dephosphorylates RB1 not provided
  15. 2010 High

    Demonstrated that Mypt1-mediated MLC dephosphorylation enables epithelial relaxation required for hindbrain ventricle expansion.

    Evidence Zebrafish mypt1 mutant, pMRLC immunostaining, myosin II inhibition rescue

    PMID:20147380

    Open questions at the time
    • Upstream kinase setting apical pMRLC not identified
  16. 2011 Medium

    Resolved isoform- and site-specificity of activating phosphorylation: PKGIα preferentially phosphorylates LZ+ MYPT1 at Ser-667 then Ser-694.

    Evidence In vitro kinase assays with LZ+/LZ− fragments and Ala/Asp mutagenesis

    PMID:21890627

    Open questions at the time
    • No cellular validation in the same study
  17. 2012 High

    Established MYPT1 as a cell-cycle scaffold: LATS1 phosphorylation at Ser-445 licenses MYPT1 to dephosphorylate and suppress PLK1, enforcing the G2 DNA-damage checkpoint.

    Evidence Phosphoproteomics, in vitro kinase assay, S445A mutant in HeLa, LATS1 KO fibroblasts, PLK1 activity and checkpoint assays

    PMID:22641346

    Open questions at the time
    • How MYPT1 is recruited to PLK1 not fully defined
  18. 2014 High

    Reconstituted the human holoenzyme to dissect inhibitory sites, showing Thr-696 phosphorylation causes autoinhibition by substrate docking while Thr-853 promotes myosin dissociation.

    Evidence Recombinant human MLCP, selective thio-phosphorylation, activity assays, mutagenesis, Co-IP in leiomyosarcoma cells

    PMID:24712327

    Open questions at the time
    • Quantitative contribution in intact cells not measured
  19. 2014 High

    Connected MYPT1 to microtubule biology and matrix assembly via a reciprocal interaction with HDAC6 controlling integrin surface density and morphogenesis.

    Evidence Co-IP with MLC and HDAC6, KD/rescue with domain mutants, integrin/fibronectin and migration assays in fibroblasts and glands

    PMID:24667306

    Open questions at the time
    • Whether MYPT1 directly regulates HDAC6 enzymatic activity not established
  20. 2014 Medium

    Defined Ser-668 as the functionally required PKG activation site, with LZ-domain dependence.

    Evidence In vitro PKG phosphorylation and MLC phosphatase assays with LZ isoforms and S668A mutant

    PMID:25168281

    Open questions at the time
    • In vivo requirement of Ser-668 not tested
  21. 2014 High

    Clarified pathway hierarchy in vivo: smooth-muscle MYPT1 restrains MLC phosphorylation and force, but PKG phosphorylation of MYPT1 is dispensable for NO/cGMP relaxation, with CPI-17/ROCK contributing.

    Evidence Conditional smooth-muscle Mypt1 KO mice, mesenteric artery force, ROCK/PKC inhibitors, NO/cGMP testing

    PMID:24951589

    Open questions at the time
    • Reconciliation with in vitro PKG-site mechanisms unresolved
  22. 2017 Medium

    Proposed an 'unfair competition' mechanism in which MLCP both sequesters and slowly dephosphorylates pCPI-17, accounting for relaxation kinetics.

    Evidence In vitro phosphatase kinetics and quantitative modeling of pCPI-17 dephosphorylation

    PMID:28387646

    Open questions at the time
    • Novel framework not independently replicated
    • In-cell validation limited
  23. 2018 Medium

    Extended checkpoint scaffolding: Chk1 phosphorylates MYPT1 at Ser-20, required for MYPT1–PP1cβ interaction and subsequent PLK1 inactivation during mitotic damage.

    Evidence Chk1 immunocomplex proteomics, in vitro kinase assay, Co-IP and PLK1 activity assays in Chk1-inhibited cells

    PMID:29262732

    Open questions at the time
    • Structural basis for Ser-20 controlling PP1cβ binding unclear
  24. 2019 Medium

    Showed TIMAP competes with MYPT1 for PP1cβ, displacing and destabilizing MYPT1 to increase MLC2 phosphorylation in endothelium.

    Evidence Reciprocal Co-IP, TIMAP overexpression/silencing, TIMAP KO lungs, active-site blocking and proteasome inhibitor experiments

    PMID:31315927

    Open questions at the time
    • Conditions favoring TIMAP vs MYPT1 occupancy of PP1cβ not defined
  25. 2019 Medium

    Added Chk2-MYPT1 axis at Ser-507 antagonizing CDK1 Ser-473 phosphorylation to control PLK1 and centrosome maturation.

    Evidence Co-IP, in vitro kinase assay, MS phosphosite mapping, S507A stable cells, γ-tubulin recruitment assays

    PMID:31416392

    Open questions at the time
    • Interplay of Chk1/Chk2/LATS1 inputs on the same scaffold not integrated
  26. 2020 High

    Identified O-GlcNAcylation as a switch maintaining MYPT1 phosphatase activity by antagonizing inhibitory phosphorylation, desensitizing cells to S1P-induced contraction.

    Evidence OGT/OGA inhibitors, site mutagenesis, 2D/3D fibroblast contraction and MLC phosphorylation assays

    PMID:32929277

    Open questions at the time
    • Specific O-GlcNAc sites for contractility control not pinpointed in this study
  27. 2020 Medium

    Mapped O-GlcNAc sites (Thr-577/Ser-585/Ser-589/Ser-601) that antagonize CDK1 Ser-473 phosphorylation, weakening MYPT1-PLK1 association and promoting premature centrosome disjunction.

    Evidence Chemoenzymatic O-GlcNAc site mapping, Thiamet-G treatment, PLK1 inhibitor rescue, MYPT1-PLK1 Co-IP in HeLa

    PMID:32295844

    Open questions at the time
    • Physiological signals altering MYPT1 O-GlcNAc during mitosis not identified
  28. 2020 High

    Broadened MYPT1/PP1β substrate range to EZH2-S21 (restraining EMT) and MLC for YAP/TAZ-driven beige adipogenesis, validated genetically in vivo.

    Evidence Co-IP with EZH2, MYPT1 KO cells, EZH2-S21A rescue, H3K9 ChIP, YAP/TAZ reporters, adipocyte-specific Mypt1 KO cold tolerance

    PMID:35293697 PMID:36175407

    Open questions at the time
    • How MYPT1 selects EZH2 vs MLC substrates not resolved
  29. 2021 Medium

    Linked MYPT1 to vascular smooth-muscle identity and blood-brain barrier integrity through an ECSIT/IL-6 axis.

    Evidence VSMC-specific Mypt1 KO mice, shMYPT1 VSMCs, proteomics, ECSIT knockdown rescue, IL-6 inhibition

    PMID:34553133

    Open questions at the time
    • Mechanistic link between MYPT1 phosphatase activity and ECSIT upregulation unclear
  30. 2021 Medium

    Generalized the O-GlcNAc contractility mechanism to a second procontractile lipid, LPA, via maintained MYPT1 activity.

    Evidence OGT/OGA inhibitors, 2D/3D fibroblast cultures, MLC phosphorylation readout

    PMID:34019870

    Open questions at the time
    • Receptor-level convergence of S1P/LPA onto MYPT1 O-GlcNAc not defined
  31. 2022 Medium

    Defined three Rho-kinase docking motifs near Thr-696/Thr-853 required for efficient MYPT1 phosphorylation, enabling selective ROCK inhibitor design.

    Evidence In vitro interaction mapping with peptides, mutagenesis, kinase activity and IC50 assays

    PMID:35204659

    Open questions at the time
    • Cellular contribution of individual docking motifs not tested
  32. 2023 Medium

    Identified SPECC1L as a direct, stable partner of the MYPT1/PP1β holoenzyme that partitions it between microtubule and actin networks.

    Evidence Co-IP, BioID proximity biotinylation, direct binding with recombinant proteins, interactome comparison

    PMID:36634848

    Open questions at the time
    • Functional consequence of network repartitioning not phenotypically resolved
  33. 2023 Medium

    Placed MYPT1 at recycling endosomes in a phosphatidylserine-dependent manner where it promotes YAP activation and target-gene transcription in cancer cells.

    Evidence Phosphatase knockdown screen, subcellular fractionation, YAP phosphorylation and CTGF assays, ATP8A1 depletion in TNBC cells

    PMID:37957190

    Open questions at the time
    • Direct YAP-pathway substrate of MYPT1/PP1 at endosomes not identified

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the many competing inputs (ROCK/PKG phosphorylation, methylation, O-GlcNAc, ubiquitination, competing subunits) are integrated to set MLCP activity in a given cell, and how MYPT1 selects between contractile and non-contractile substrates (PLK1, EZH2, YAP pathway), remains unresolved.
  • No unified model integrating all PTM inputs
  • Substrate-selection determinants beyond contractility undefined
  • Structural basis of myosin- vs non-myosin-substrate targeting unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008092 cytoskeletal protein binding 3 GO:0060090 molecular adaptor activity 3 GO:0098772 molecular function regulator activity 3 GO:0140096 catalytic activity, acting on a protein 3
Localization
GO:0005856 cytoskeleton 3 GO:0005815 microtubule organizing center 2 GO:0005634 nucleus 1 GO:0005768 endosome 1 GO:0005829 cytosol 1
Pathway
R-HSA-1266738 Developmental Biology 3 R-HSA-162582 Signal Transduction 3 R-HSA-1640170 Cell Cycle 3 R-HSA-392499 Metabolism of proteins 3 R-HSA-397014 Muscle contraction 2
Partners
EZH2HDAC6PLK1PPP1CBPRKG1ROCK1SIAH2SPECC1L
Complex memberships
myosin light chain phosphatase (MLCP / MYPT1-PP1cβ holoenzyme)

Evidence

Reading pass · 34 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 Rho-kinase (Rho-associated kinase) directly phosphorylates MBS/MYPT1 at Thr-697 and Ser-854 in vivo, downstream of Rho, inactivating myosin phosphatase activity; phosphorylated MYPT1 localizes to actin stress fibers, the leading edge of migrating cells, and the cleavage furrow during cytokinesis. Site-specific phospho-antibodies, microinjection of dominant-negative Rho-kinase/C3 ADP-ribosyltransferase, immunofluorescence localization in MDCK and REF52 cells The Journal of Cell Biology High 10579722
2000 PKC phosphorylates Thr-34 (adjacent to the PP1c-binding motif KVKF) and a second site within the ankyrin repeats of MYPT1(1-296), attenuating the stimulatory effect of MYPT1 on myosin light chain phosphatase activity and reducing binding of both PP1c and phospho-MLC20 to MYPT1. In vitro phosphorylation assays with recombinant MYPT1 fragments, phosphatase activity assays, binding competition experiments FEBS Letters Medium 11068043
2002 Phosphorylated MBS/MYPT1 is highly resistant to dephosphorylation by type-1, -2A, -2B, and -2C phosphatases in vitro, whereas CPI-17 phosphorylation is rapidly reversed by PP2A and PP2C; arachidonic acid inhibits PP2A activity toward both MBS and CPI-17. In vitro dephosphorylation assays with purified protein phosphatases PP1, PP2A, PP2B, PP2C; smooth muscle fiber experiments FEBS Letters Medium 11943207
2004 PKG and PKA phosphorylate MYPT1 at Ser-695 (adjacent to the inhibitory Thr-696), and this phosphorylation sterically prevents phosphorylation of Thr-696 by MYPT1 kinase (ZIPK), providing a mutual exclusion mechanism for cGMP/cAMP-dependent Ca2+ desensitization in smooth muscle. In vitro kinase assays with recombinant MYPT1, ileum smooth muscle permeabilization experiments with constitutively active MYPT1K and 8-bromo-cGMP, western blotting with phospho-specific antibodies The Journal of Biological Chemistry High 15194681
2004 The N-terminal region of MYPT1 (residues 1–296, with residues 297–374 playing a supplemental role) is sufficient to enhance myosin light chain phosphorylation and Ca2+-sensitized contraction in intact coronary artery when introduced via TAT-mediated protein transduction, identifying this domain as critical for interaction with the catalytic subunit and regulation of endogenous myosin phosphatase. HIV Tat protein-mediated transduction of MYPT1 fragments into porcine coronary arterial strips, isometric force recording, MLC phosphorylation measurement Arteriosclerosis, Thrombosis, and Vascular Biology Medium 14707041
2005 Assembly of MYPT1 with PP1δ catalytic subunit is required for cytoplasmic/myofilament localization of MYPT1; expressed alone, MYPT1 accumulates in the nucleus, but co-expression with PP1 redirects it to the cytosol and myofilaments. The F38A PP1-binding mutant of MYPT1 remains nuclear even when PP1 is co-expressed. The MYPT1 C-terminus acts as an autoinhibitory domain for actin cytoskeleton reorganization. Transient expression of epitope-tagged MYPT1 and HA-PP1 in REF52 fibroblasts, immunofluorescence microscopy, F38A mutagenesis Cell Motility and the Cytoskeleton Medium 16106448
2006 The interaction between MYPT1 and PKGIα requires the amino acid region 888–928 of MYPT1 containing an RK motif (Arg916-Lys917); mutation of this RK motif to EE eliminates PKGIα binding, and the leucine zipper domain is not sufficient alone for this interaction. Co-immunoprecipitation of MYPT1 deletion/point-mutation fragments with PKGIα in avian smooth muscle tissue lysates American Journal of Physiology. Cell Physiology Medium 16870832
2008 Zebrafish Mypt1 mediates coordination between lateral plate mesoderm and endoderm cell movements by regulating actin filament organization; mypt1 mutation causes abnormal actin bundling, disrupted LPM/endoderm organization, and misalignment of Bmp2a-producing cells relative to the liver primordium, leading to hepatoblast apoptosis and liver agenesis. Zebrafish genetic mutation analysis, 3D cell movement tracking, immunofluorescence for actin and Bmp2a expression, hepatoblast proliferation/apoptosis assays Development High 18776143
2008 Apolipoprotein(a), via the strong lysine-binding site in KIV(10'), activates a Rho/Rho kinase signaling pathway leading to increased MYPT1 phosphorylation, decreased myosin light chain phosphatase activity, increased MLC phosphorylation, stress fiber formation, endothelial cell contraction, and barrier permeability. Treatment of HUVECs with recombinant apo(a) variants, ROCK inhibitor Y27632 and ε-aminocaproic acid rescue, western blotting for MYPT1 phosphorylation, permeability assays The Journal of Biological Chemistry Medium 18776185
2009 The E3 ubiquitin ligase SIAH2 directly interacts with MYPT1 via its substrate-binding domain (aa 116–324) and a degenerate Siah-binding motif (RLAYVAP, aa 493–499) in MYPT1, promoting proteasomal degradation of MYPT1 in mammalian cells including neurons and glia. Co-immunoprecipitation, domain-mapping with deletion constructs, proteasome inhibitor experiments in mammalian cells Experimental Cell Research Medium 19744480
2009 MYPT1 is a substrate for the asparaginyl hydroxylase FIH (factor inhibiting HIF); FIH hydroxylates asparagine residues within the ankyrin repeat domain of MYPT1 at three sites, both in cultured cells and in endogenous protein from animal tissue, and MYPT1 expression competes with HIF-CAD for FIH, thereby enhancing HIF activity. FIH hydroxylation assays in cell culture and purified endogenous protein, FIH knockdown/overexpression, HIF-CAD competition assays The Biochemical Journal Medium 19245366
2010 In zebrafish, loss of mypt1 results in constitutively elevated phosphorylated myosin regulatory light chain (pMRLC) concentrated at the apical surface and rhombomere boundaries, causing impaired neuroepithelial stretching and failure of brain ventricle lumen expansion; inhibition of myosin II rescues the small-ventricle, cell-shape, and rhombomere morphology defects, demonstrating that mypt1-mediated myosin dephosphorylation is required for epithelial relaxation during hindbrain morphogenesis. Zebrafish mypt1 mutant analysis, 3D reconstruction of hindbrain, pMRLC immunostaining, pharmacological myosin II inhibition rescue experiments Development High 20147380
2010 MYPT1(1-98) exhibits a two-domain structure in solution: residues 1–40 are intrinsically disordered with a 25%-populated transient α-helix, while residues 41–98 form a well-structured ankyrin-repeat domain. The transient α-helix becomes fully structured upon PP1 binding, indicating it is a key driver of MYPT1-PP1 holoenzyme formation. NMR spectroscopy and biophysical ensemble modeling of free MYPT1(1-98) compared to the PP1-bound state Journal of the American Chemical Society High 21142030
2010 MYPT1 is methylated at Lys-442 by the histone methyltransferase SETD7 and demethylated by LSD1 (KDM1); methylation stabilizes MYPT1 protein by protecting it from ubiquitin-proteasome degradation, and LSD1-mediated demethylation destabilizes MYPT1, reducing RB1 dephosphorylation and promoting cell cycle progression. In vitro methylation assays, LSD1 and SETD7 knockdown/overexpression in cancer cells, western blotting for MYPT1 levels and RB1-Ser807/811 phosphorylation, SETD7-deficient murine cells Cancer Research High 21115810
2011 LZ+ MYPT1 isoforms are preferentially and rapidly phosphorylated by PKGIα at Ser-667 and Ser-694, whereas LZ− isoforms are poor PKGIα substrates; Ser-667 phosphorylation is kinetically prioritized over Ser-694 and may be a primary determinant of MLC phosphatase activation by the NO/cGMP pathway. In vitro kinase assays with purified LZ+/LZ− MYPT1 fragments, Ala/Asp substitution mutagenesis at Ser-667 and Ser-694 The Journal of Biological Chemistry Medium 21890627
2012 LATS1 kinase directly phosphorylates MYPT1 at Ser-445; this phosphorylation enables MYPT1 to dephosphorylate PLK1-Thr210, suppressing PLK1 activity. Loss of LATS1 or the S445A MYPT1 mutant leads to increased PLK1 activity, and DNA damage-induced LATS1 activation suppresses PLK1 via MYPT1-S445 phosphorylation to enforce the G2 DNA damage checkpoint. Phosphoproteomic screening, in vitro kinase assay, MYPT1 S445A mutant expression in HeLa cells, LATS1 KO mouse fibroblasts, PLK1 activity assays, G2 checkpoint analysis after DNA damage The Journal of Cell Biology High 22641346
2014 Reconstituted recombinant human MLCP complex revealed that selective ROCK-induced thio-phosphorylation of MYPT1 at Thr-696 inhibits phosphatase activity ~30% via autoinhibition (substrate docking at the active site), whereas Thr-853 phosphorylation does not directly alter phosphatase activity but facilitates Thr-853 phosphorylation sequentially after Thr-696; serum stimulation dissociates MYPT1 from myosin and PP1C in parallel with increased Thr-853 phosphorylation. Recombinant human MLCP reconstitution from mammalian cell lysates, selective thio-phosphorylation, phosphatase activity assays, mutagenesis to block docking, autodephosphorylation assays, co-immunoprecipitation in leiomyosarcoma cells Biochemistry High 24712327
2014 MYPT1 physically interacts with both myosin light chain (via its myosin-binding C-terminal domain) and HDAC6 (a microtubule deacetylase), reciprocally coordinating cellular contractility and microtubule acetylation; this balance controls α5β1 integrin surface density to modulate fibronectin matrix assembly, cell migration, and branching morphogenesis. Co-immunoprecipitation of MYPT1 with MLC and HDAC6 in fibroblasts and developing glands, MYPT1 knockdown/rescue with functional domain mutants, integrin surface density measurement, fibronectin matrix assembly and migration assays Nature Communications High 24667306
2014 S668 phosphorylation of LZ+ MYPT1 by PKG is required for PKG-mediated Ca2+-independent activation of MLC phosphatase; an S668A mutation prevents this activation, and the LZ domain of MYPT1 is required for PKG to phosphorylate S668. In vitro PKG phosphorylation assays with LZ+/LZ− MYPT1 isoforms and S668A mutant, MLC phosphatase activity assays Archives of Biochemistry and Biophysics Medium 25168281
2017 Unfair competition mechanism: MLCP (PP1-MYPT1 complex) itself is the critical enzyme for dephosphorylating pCPI-17, not other phosphatases; MLCP protects pCPI-17 from other phosphatases (mutual sequestration) while slowly dephosphorylating it at a rate sufficient to account for the speed of pCPI-17 inactivation during smooth muscle relaxation. In vitro phosphatase kinetics, reconstituted MLCP activity assays, quantitative modeling of pCPI-17 dephosphorylation rates in smooth muscle eLife Medium 28387646
2018 Chk1 directly phosphorylates MYPT1 at Ser-20, which is essential for MYPT1–PP1cβ interaction and subsequent PLK1 dephosphorylation/inactivation; Chk1 inhibition during mitotic damage abolishes Ser-20 phosphorylation, and Chk1 also regulates MYPT1 protein stability. Proteomic screen identifying MYPT1 in Chk1 immunocomplex, in vitro kinase assay for Ser-20 phosphorylation, Co-IP of MYPT1 with PP1cβ in Chk1-inhibited cells, PLK1 activity assays Cell Cycle Medium 29262732
2018 Chlamydia trachomatis inclusion membrane protein CT228 recruits MYPT1 to the chlamydial inclusion; genetic deletion of CT228 abolishes MYPT1 recruitment and increases extrusion-mediated host cell exit, indicating that CT228–MYPT1 interaction regulates myosin phosphatase activity at the inclusion to control the mode of bacterial egress. Targeted chromosomal mutation of CT228 (TargeTron), co-localization/recruitment assays, quantification of extrusion vs. lysis exit, murine intravaginal infection model Frontiers in Cellular and Infection Microbiology Medium 30555802
2019 TIMAP (a MYPT family member) competes with MYPT1 for PP1cβ binding in endothelial cells; excess TIMAP displaces MYPT1 from PP1cβ, causing proteasomal degradation of MYPT1 and blocking the PP1cβ active site, thereby increasing MLC2 phosphorylation. Co-immunoprecipitation of TIMAP/PP1cβ/MLC2 from EC lysates, TIMAP overexpression/silencing, TIMAP KO mouse lungs, microcystin-LR active-site blocking assay, proteasome inhibitor experiments The Journal of Biological Chemistry Medium 31315927
2019 Chk2 directly phosphorylates MYPT1 at Ser-507 in vitro and in vivo, antagonizing CDK1-dependent phosphorylation at Ser-473; this regulatory axis controls PLK1 activity and centrosome maturation (γ-tubulin recruitment), as MYPT1-S507A mutant cells phenocopy PLK1 inhibition defects. Co-IP identifying Chk2–MYPT1 interaction, in vitro kinase assay for S507, stable MYPT1-S507A transfectants, γ-tubulin centrosome recruitment assays, LC-MS/MS phosphosite identification Cell Cycle Medium 31416392
2020 O-GlcNAc modification of MYPT1 inhibits its phosphorylation and maintains its phosphatase activity, thereby blocking sphingosine-1-phosphate-induced MLC phosphorylation and cellular contraction in fibroblasts; elevated O-GlcNAc levels desensitize cells to S1P-induced contraction through this MYPT1-dependent mechanism. OGT/OGA chemical inhibitors, site-specific O-GlcNAc mutagenesis, 2D cell culture and 3D collagen matrix wound-healing models, western blotting for MLC phosphorylation Nature Chemical Biology High 32929277
2020 MYPT1 is O-GlcNAcylated at Thr-577, Ser-585, Ser-589, and Ser-601; these modifications antagonize CDK1-dependent phosphorylation at Ser-473, attenuating MYPT1 association with PLK1, thereby promoting PLK1 activity and premature centrosome disjunction when O-GlcNAc levels are elevated. Chemoenzymatic labeling and bioorthogonal conjugation for O-GlcNAc site mapping, OGA inhibitor Thiamet-G treatment in HeLa cells, PLK1 inhibitor rescue, co-IP of MYPT1 with PLK1 The Journal of Biological Chemistry Medium 32295844
2020 MYPT1/PP1β phosphatase dephosphorylates EZH2 at S21, counteracting AKT-mediated phosphorylation; MYPT1 knockout promotes EZH2-mediated H3K9 demethylation and EMT gene programs. MYPT1-PP1β also dephosphorylates myosin light chain to regulate actomyosin tension and YAP/TAZ activation, which directly drives Ucp1 expression in beige adipogenesis. Co-IP of MYPT1 with EZH2, MYPT1 KO in lens epithelial and pre-adipocyte cells, EZH2-S21A mutant rescue, H3K9 methylation ChIP, MLC dephosphorylation assays, YAP/TAZ reporter assays, in vivo cold tolerance in adipocyte-specific Mypt1 KO mice Advanced Science / Nature Communications High 35293697 36175407
2021 MYPT1 deficiency in vascular smooth muscle cells induces phenotypic switching to a synthetic VSMC phenotype and disrupts blood-brain barrier integrity via upregulation of ECSIT and subsequent IL-6 expression; ECSIT knockdown rescues both synthetic VSMC phenotypic switching and BBB disruption. VSMC-specific MYPT1 KO mice, lentiviral shMYPT1 in cultured VSMCs, proteomic identification of ECSIT as downstream mediator, ECSIT knockdown rescue, IL-6 inhibition assays iScience Medium 34553133
2021 O-GlcNAc modification of MYPT1 also controls fibroblast contraction induced by lysophosphatidic acid (LPA) by maintaining MYPT1 phosphatase activity and preventing MLC phosphorylation, extending the S1P mechanism to a second procontractile lipid pathway. OGT/OGA inhibitors, 2D and 3D mouse and primary human dermal fibroblast cultures, western blotting for MLC phosphorylation, biochemical rescue experiments The Journal of Biological Chemistry Medium 34019870
2022 Three docking motifs in MYPT1 (DM1: DLQEAEKTIGRS; DM2: KSQPKSIRERRRPR; DM3: RKARSRQAR) near the Thr-696 and Thr-853 phosphorylation sites mediate direct interaction with Rho-kinase and are required for efficient phosphorylation; combined pseudosubstrate + DM peptides serve as potent selective Rho-kinase inhibitors. In vitro Rho-kinase–MYPT1 interaction mapping with peptide fragments and mutagenesis, kinase activity assays, inhibitor IC50 measurements Biomolecules Medium 35204659
2023 SPECC1L directly binds MYPT1 and exists in a stable complex with the MYPT1/PP1β holoenzyme in non-muscle cells; SPECC1L modulates the distribution of the MYPT1/PP1β complex between microtubule and filamentous actin networks. Co-immunoprecipitation, proximity biotinylation (BioID), direct binding assays with recombinant proteins, interactome comparison of SPECC1L and MYPT1 The Journal of Biological Chemistry Medium 36634848
2023 PPP1R12A (MYPT1) localizes to recycling endosomes (REs) in a phosphatidylserine-dependent manner; knockdown of PPP1R12A increases phosphorylated (inactive) YAP and reduces nuclear YAP and YAP target gene (CTGF) transcription in triple-negative breast cancer cells; ATP8A1-mediated PS enrichment in RE membranes is required for RE retention of PPP1R12A. Knockdown screen of 11 phosphatases, subcellular fractionation (microsomal vs. cytosolic), YAP phosphorylation western blotting, CTGF transcription assays, ATP8A1 depletion, cancer cell proliferation assays Scientific Reports Medium 37957190
2005 MYPT1 targeted disruption (homozygous) results in embryonic lethality before E7.5 in mice, establishing that MYPT1 is essential for early mouse embryogenesis; heterozygotes show no phenotype and normal MYPT1 expression levels. Gene targeting in mice (knockout), embryonic lethal phenotyping, heterozygote characterization by western blotting Transgenic Research High 16145842
2014 Smooth muscle-specific MYPT1 knockout in adult mice enhances myosin regulatory light chain phosphorylation and contractile force in mesenteric arteries; CPI-17 phosphorylation by Rho-kinase (ROCK) contributes to enhanced contractility in MYPT1-deficient arteries, while PKG phosphorylation of MYPT1 is not required for NO/cGMP-mediated relaxation. Conditional smooth muscle-specific Mypt1 knockout mice, isometric force measurement in isolated mesenteric arteries, ROCK and PKC inhibitor experiments, MLC and CPI-17 phosphorylation western blotting, NO/cGMP pathway testing The Journal of Biological Chemistry High 24951589

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1999 Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. The Journal of cell biology 474 10579722
2010 Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer research 178 21115810
2004 Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides. The Journal of biological chemistry 176 15194681
2005 Thromboxane A2-induced contraction of rat caudal arterial smooth muscle involves activation of Ca2+ entry and Ca2+ sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. The Biochemical journal 157 15823093
2020 Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness. Molecular cancer 98 31926547
2014 Myosin phosphatase target subunit 1 (MYPT1) regulates the contraction and relaxation of vascular smooth muscle and maintains blood pressure. The Journal of biological chemistry 86 24951589
2003 Chronic treatment with interleukin-1beta attenuates contractions by decreasing the activities of CPI-17 and MYPT-1 in intestinal smooth muscle. The Journal of biological chemistry 85 14512413
2017 MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. Molecular cancer 77 28241827
2008 Mypt1-mediated spatial positioning of Bmp2-producing cells is essential for liver organogenesis. Development (Cambridge, England) 74 18776143
2010 Epithelial relaxation mediated by the myosin phosphatase regulator Mypt1 is required for brain ventricle lumen expansion and hindbrain morphogenesis. Development (Cambridge, England) 72 20147380
2004 Gq/G13 signaling by ET-1 in smooth muscle: MYPT1 phosphorylation via ETA and CPI-17 dephosphorylation via ETB. American journal of physiology. Cell physiology 67 15475516
2014 Reconstituted human myosin light chain phosphatase reveals distinct roles of two inhibitory phosphorylation sites of the regulatory subunit, MYPT1. Biochemistry 64 24712327
2004 Excessive Myosin activity in mbs mutants causes photoreceptor movement out of the Drosophila eye disc epithelium. Molecular biology of the cell 61 15075368
2008 Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. The Journal of biological chemistry 58 18776185
2014 MYPT1 regulates contractility and microtubule acetylation to modulate integrin adhesions and matrix assembly. Nature communications 56 24667306
1997 Localization of the gene coding for myosin phosphatase, target subunit 1 (MYPT1) to human chromosome 12q15-q21. Genomics 45 9286714
2012 LATS1/WARTS phosphorylates MYPT1 to counteract PLK1 and regulate mammalian mitotic progression. The Journal of cell biology 44 22641346
2019 Loss-of-Function Variants in PPP1R12A: From Isolated Sex Reversal to Holoprosencephaly Spectrum and Urogenital Malformations. American journal of human genetics 43 31883643
2006 MYPT1 mutants demonstrate the importance of aa 888-928 for the interaction with PKGIalpha. American journal of physiology. Cell physiology 43 16870832
2021 Novel circular RNA circSOBP governs amoeboid migration through the regulation of the miR-141-3p/MYPT1/p-MLC2 axis in prostate cancer. Clinical and translational medicine 42 33784000
2009 mbs: modifying Hudson's ms software to generate samples of DNA sequences with a biallelic site under selection. BMC bioinformatics 42 19480708
2010 Structural signature of the MYPT1-PP1 interaction. Journal of the American Chemical Society 41 21142030
2005 The targeted disruption of the MYPT1 gene results in embryonic lethality. Transgenic research 41 16145842
2002 Dephosphorylation of the two regulatory components of myosin phosphatase, MBS and CPI17. FEBS letters 41 11943207
2011 Phasic contractions of isolated human myometrium are associated with Rho-kinase (ROCK)-dependent phosphorylation of myosin phosphatase-targeting subunit (MYPT1). Molecular human reproduction 39 22155728
2014 The production of nitrous oxide by the heme/nonheme diiron center of engineered myoglobins (Fe(B)Mbs) proceeds through a trans-iron-nitrosyl dimer. Journal of the American Chemical Society 38 24432820
2011 MYPT1 protein isoforms are differentially phosphorylated by protein kinase G. The Journal of biological chemistry 38 21890627
2006 Urocortin-induced decrease in Ca2+ sensitivity of contraction in mouse tail arteries is attributable to cAMP-dependent dephosphorylation of MYPT1 and activation of myosin light chain phosphatase. Circulation research 38 16574904
2005 Assembly of MYPT1 with protein phosphatase-1 in fibroblasts redirects localization and reorganizes the actin cytoskeleton. Cell motility and the cytoskeleton 38 16106448
2000 Phosphorylation of MYPT1 by protein kinase C attenuates interaction with PP1 catalytic subunit and the 20 kDa light chain of myosin. FEBS letters 37 11068043
2018 Connexin 40 regulates lung endothelial permeability in acute lung injury via the ROCK1-MYPT1- MLC20 pathway. American journal of physiology. Lung cellular and molecular physiology 35 30234377
2008 G(q)-dependent signalling by the lysophosphatidic acid receptor LPA(3) in gastric smooth muscle: reciprocal regulation of MYPT1 phosphorylation by Rho kinase and cAMP-independent PKA. The Biochemical journal 35 18237278
2020 MYPT1 O-GlcNAc modification regulates sphingosine-1-phosphate mediated contraction. Nature chemical biology 34 32929277
2017 Airborne particulate matter in vitro exposure induces cytoskeleton remodeling through activation of the ROCK-MYPT1-MLC pathway in A549 epithelial lung cells. Toxicology letters 33 28279687
2005 Alpha1-adrenoceptor-mediated phosphorylation of MYPT-1 and CPI-17 in the uterine artery: role of ERK/PKC. American journal of physiology. Heart and circulatory physiology 32 15665049
2020 Structure of the respiratory MBS complex reveals iron-sulfur cluster catalyzed sulfane sulfur reduction in ancient life. Nature communications 31 33230146
2011 Synchronous phosphorylation of CPI-17 and MYPT1 is essential for inducing Ca(2+) sensitization in intestinal smooth muscle. Neurogastroenterology and motility 29 22004286
2018 Regulation of Smooth Muscle Myosin Light Chain Phosphatase by Multisite Phosphorylation of the Myosin Targeting Subunit, MYPT1. Cardiovascular & hematological disorders drug targets 28 29577868
2018 Genetic Inactivation of Chlamydia trachomatis Inclusion Membrane Protein CT228 Alters MYPT1 Recruitment, Extrusion Production, and Longevity of Infection. Frontiers in cellular and infection microbiology 28 30555802
2022 MYPT1/PP1-Mediated EZH2 Dephosphorylation at S21 Promotes Epithelial-Mesenchymal Transition in Fibrosis through Control of Multiple Families of Genes. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 27 35293697
2017 Ferulic acid relaxed rat aortic, small mesenteric and coronary arteries by blocking voltage-gated calcium channel and calcium desensitization via dephosphorylation of ERK1/2 and MYPT1. European journal of pharmacology 27 28989085
2011 Regulation of basal LC20 phosphorylation by MYPT1 and CPI-17 in murine gastric antrum, gastric fundus, and proximal colon smooth muscles. Neurogastroenterology and motility 27 21883701
2021 Synthetic VSMCs induce BBB disruption mediated by MYPT1 in ischemic stroke. iScience 26 34553133
2014 Differential phosphorylation of LZ+/LZ- MYPT1 isoforms regulates MLC phosphatase activity. Archives of biochemistry and biophysics 26 25168281
2011 Spectroscopic characterization of mononitrosyl complexes in heme--nonheme diiron centers within the myoglobin scaffold (Fe(B)Mbs): relevance to denitrifying NO reductase. Biochemistry 25 21634416
2020 Rosmarinic Acid Prevents Radiation-Induced Pulmonary Fibrosis Through Attenuation of ROS/MYPT1/TGFβ1 Signaling Via miR-19b-3p. Dose-response : a publication of International Hormesis Society 23 33149731
2009 Regulation of MYPT1 stability by the E3 ubiquitin ligase SIAH2. Experimental cell research 23 19744480
2009 MYPT1, the targeting subunit of smooth-muscle myosin phosphatase, is a substrate for the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH). The Biochemical journal 22 19245366
2020 O-GlcNAcylation of myosin phosphatase targeting subunit 1 (MYPT1) dictates timely disjunction of centrosomes. The Journal of biological chemistry 21 32295844
2009 Volatile anesthetics inhibit angiotensin II-induced vascular contraction by modulating myosin light chain phosphatase inhibiting protein, CPI-17 and regulatory subunit, MYPT1 phosphorylation. Anesthesia and analgesia 20 19608811
2009 Degradation of leucine zipper-positive isoform of MYPT1 may contribute to development of nitrate tolerance. Cardiovascular research 20 19939965
2011 Hypoxia modulates the expression of leucine zipper-positive MYPT1 and its interaction with protein kinase G and Rho kinases in pulmonary arterial smooth muscle cells. Pulmonary circulation 19 22530104
2010 Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis 18 21035804
2014 TRA2β controls Mypt1 exon 24 splicing in the developmental maturation of mouse mesenteric artery smooth muscle. American journal of physiology. Cell physiology 17 25428883
2018 The involvement of phosphorylation of myosin phosphatase targeting subunit 1 (MYPT1) and MYPT1 isoform expression in NO/cGMP mediated differential vasoregulation of cerebral arteries compared to systemic arteries. Acta physiologica (Oxford, England) 16 29694711
2012 Decreased myosin phosphatase target subunit 1(MYPT1) phosphorylation via attenuated rho kinase and zipper-interacting kinase activities in edematous intestinal smooth muscle. Neurogastroenterology and motility 16 22235829
2012 Angiotensin II regulates the LARG/RhoA/MYPT1 axis in rat vascular smooth muscle in vitro. Acta pharmacologica Sinica 16 23123644
2013 ROS-mediated downregulation of MYPT1 in smooth muscle cells: a potential mechanism for the aberrant contractility in atherosclerosis. Laboratory investigation; a journal of technical methods and pathology 15 23419712
2009 Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression. PloS one 15 19357768
2006 Ca2+-desensitizing hypoxic vasorelaxation: pivotal role for the myosin binding subunit of myosin phosphatase (MYPT1) in porcine coronary artery. The Journal of physiology 15 16439434
2023 NUAK1 governs centrosome replication in pancreatic cancer via MYPT1/PP1β and GSK3β-dependent regulation of PLK4. Molecular oncology 14 36975767
2022 MYPT1-PP1β phosphatase negatively regulates both chromatin landscape and co-activator recruitment for beige adipogenesis. Nature communications 14 36175407
2013 Differential vasodilation of human placental and myometrial arteries related to myofilament Ca(2+)-desensitization and the expression of Hsp20 but not MYPT1. Molecular human reproduction 14 23775458
2010 Increased degradation of MYPT1 contributes to the development of tolerance to nitric oxide in porcine pulmonary artery. American journal of physiology. Lung cellular and molecular physiology 14 20418385
1999 Identification of MYPT1 and NIPP1 as subunits of protein phosphatase 1 in rat liver cytosol. FEBS letters 14 10428496
2001 Molecular cloning and analysis of the 5'-flanking region of the human MYPT1 gene. Biochimica et biophysica acta 13 11342221
2021 MYPT1, regulated by miR-19b-3p inhibits the progression of non-small cell lung cancer via inhibiting the activation of wnt/β-catenin signaling. Life sciences 12 33964297
2018 MYPT1 is targeted by miR-145 inhibiting viability, migration and invasion in 2D and 3D HeLa cultures. Biochemical and biophysical research communications 12 30446228
2017 Unfair competition governs the interaction of pCPI-17 with myosin phosphatase (PP1-MYPT1). eLife 12 28387646
2004 Transduction of the N-terminal fragments of MYPT1 enhances myofilament Ca2+ sensitivity in an intact coronary artery. Arteriosclerosis, thrombosis, and vascular biology 12 14707041
2023 SPECC1L binds the myosin phosphatase complex MYPT1/PP1β and can regulate its distribution between microtubules and filamentous actin. The Journal of biological chemistry 11 36634848
2023 Clinical report and genetic analysis of a neonate with genitourinary and/or brain malformation syndrome caused by a non-coding sequence variant of PPP1R12A. Molecular genetics & genomic medicine 10 37272772
2022 An ultrasensitive electrochemical biosensor for bisphenol A based on aptamer-modified MrGO@AuNPs and ssDNA-functionalized AuNP@MBs synergistic amplification. Chemosphere 10 36351468
2019 Chk2-dependent phosphorylation of myosin phosphatase targeting subunit 1 (MYPT1) regulates centrosome maturation. Cell cycle (Georgetown, Tex.) 10 31416392
2018 Chk1 modulates the interaction between myosin phosphatase targeting protein 1 (MYPT1) and protein phosphatase 1cβ (PP1cβ). Cell cycle (Georgetown, Tex.) 10 29262732
2018 Overexpression of Myosin Phosphatase Target Subunit 1 (MYPT1) Inhibits Tumor Progression and Metastasis of Gastric Cancer. Medical science monitor : international medical journal of experimental and clinical research 10 29687789
2018 Inhibition of miR-124 improves neonatal necrotizing enterocolitis via an MYPT1 and TLR9 signal regulation mechanism. Journal of cellular physiology 10 30480807
2023 Buffered loofah supported Microalgae-Bacteria symbiotic (MBS) system for enhanced nitrogen removal from rare earth element tailings (REEs) wastewater: Performance and functional gene analysis. Chemosphere 9 36858117
2022 Shuxuetong injection and its peptides enhance angiogenesis after hindlimb ischemia by activating the MYPT1/LIMK1/Cofilin pathway. Journal of ethnopharmacology 9 35248678
2021 The ROCK inhibitor Y-27632 ameliorates blood-spinal cord barrier disruption by reducing tight junction protein degradation via the MYPT1-MLC2 pathway after spinal cord injury in rats. Brain research 9 34634287
2019 TIMAP inhibits endothelial myosin light chain phosphatase by competing with MYPT1 for the catalytic protein phosphatase 1 subunit PP1cβ. The Journal of biological chemistry 9 31315927
2016 Effect of Outer-Sphere Side Chain Substitutions on the Fate of the trans Iron-Nitrosyl Dimer in Heme/Nonheme Engineered Myoglobins (Fe(B)Mbs): Insights into the Mechanism of Denitrifying NO Reductases. Biochemistry 9 27003474
2016 Characterization of isoform expression and subcellular distribution of MYPT1 in intestinal epithelial cells. Gene 9 27129938
2011 Heterogeneity in relaxation of different sized porcine coronary arteries to nitrovasodilators: role of PKG and MYPT1. Pflugers Archiv : European journal of physiology 9 22020732
2007 Preserved expression of GLUT4 prevents enhanced agonist-induced vascular reactivity and MYPT1 phosphorylation in hypertensive mouse aorta. American journal of physiology. Heart and circulatory physiology 9 17369465
2015 PPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based Chemotherapy. Mediators of inflammation 8 26113782
2023 MYPT1SMKO Mice Function as a Novel Spontaneous Age- and Hypertension-Dependent Animal Model of CSVD. Translational stroke research 7 36843141
2023 Highly sensitive detection of CYFRA21-1 with a SERS sensing platform based on the MBs enrichment strategy and antibody-DNA-mediated CHA amplification. Frontiers in bioengineering and biotechnology 7 37635996
2023 PPP1R12A is a recycling endosomal phosphatase that facilitates YAP activation. Scientific reports 7 37957190
1997 Dark and light neurons in the human brain, with special reference to their reactions to Golgi's silver nitrate, luxol fast blue MBS and azocarmine G. Archives of histology and cytology 7 9376174
2023 MBS: a genome browser annotation track for high-confident microRNA binding sites in whole human transcriptome. Database : the journal of biological databases and curation 6 37114805
2022 Identification of the Kinase-Substrate Recognition Interface between MYPT1 and Rho-Kinase. Biomolecules 6 35204659
2019 A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. Human pathology 6 30946934
2016 Atorvastatin acutely reduces the reactivity to spasmogens in rat aorta: implication of the inhibition of geranylgeranylation and MYPT-1 phosphorylation. Fundamental & clinical pharmacology 6 26610064
2016 Carbachol-induced signaling through Thr696-phosphorylation of myosin phosphatase-targeting subunit 1 (MYPT1) in rat bladder smooth muscle cells. International urology and nephrology 6 27118568
2022 MYPT1 reduction is a pathogenic factor of erectile dysfunction. Communications biology 5 35879418
2006 [Urocortin decreases phosphorylation of MYPT1 and increases the myosin phosphatase activity via elevation of the intracellular level of cAMP]. Biofizika 5 17131811
2024 Functional analysis of a novel nonsense PPP1R12A variant in a Chinese family with infantile epilepsy. BMC medical genomics 4 39334371
2023 A Dynamic and Pseudo-Homogeneous MBs-icELISA for the Early Detection of Aflatoxin B1 in Food and Feed. Toxins 4 37999523
2021 O-GlcNAc modification of MYPT1 modulates lysophosphatidic acid-induced cell contraction in fibroblasts. The Journal of biological chemistry 4 34019870

Missed literature

Know a paper Affinage missed for PPP1R12A? Flag it for the maintainers and the community.

No submissions yet.